

**Remarks**

Claims 3, 6-9, 12, 15, 16, 19, 20, 24 and 25 have been canceled.

Claims 1, 2 and 4 have been withdrawn as directed to non-elected subject matter, Group I invention drawn to uses of the compounds. Applicants preserve the right for consideration of rejoinder of Claims 1, 2 and 4.

Claim 5 has been amended to incorporate limitations of dependent Claims 6, 9 and 15 for values of n, Ar and R<sup>2</sup> respectively. In addition, Claim 5 has been amended to limit R<sup>1</sup> to values other than hydrogen. Applicants assert the amendment raises no issue of new subject matter.

Claims 13, 14, 17 and 18 have been amended to refer to Claim 10, the claim from which they depend.

A new claim directed to a species, Claim 26, has been added. The basis for Claims 26 can be found at least in Example 11 of the international application. Applicants assert the amendments raise no issue of new subject matter.

**Election**

The Examiner asserts restriction of the invention between the use (Group I) and compound (Group II) claims is required. Further, the Examiner advises in order for the response to be considered complete, it must include (i) an election of species for examination purposes, (ii) an election of a single invention selected from Group I and II, and (iii) identification of the claims encompassing the elected invention.

Applicants elect without traverse the species of Example 11, 5-(3-Chlorophenylethynyl)-nicotinonitrile for examination purposes.

Further, applicants elect without traverse the invention of Group II, claims to compounds and processes for their preparation as well as pharmaceutical compositions.

As currently amended, Claims 5, 10, 11, 13, 14, 17, 18, 21-23 and 26 encompass the Group I invention as well as the elected species, 5-(3-Chlorophenylethynyl)-nicotinonitrile.

In view of the amendments and election, Examiner is requested to consider the application. Allowance of Claims 5, 10, 11, 13, 14, 17, 18, 21-23 is kindly solicited. Should it be helpful to expedite prosecution, the Examiner is encouraged to telephone.

Respectfully submitted,

/Mark A. Winter/

Mark A. Winter  
Agent for Applicants  
Registration No. 53,782  
Phone: 317-276-5362

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

November 3, 2008

---